Antidepressants in panic disorder: Clinical and preclinical mechanisms

Journal of Clinical Psychiatry

Volumn 59, Issue SUPPL.8, 1998, Pages 24-29

  Nutt, David J ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

(3 CHLOROPHENYL)PIPERAZINE; 5 HYDROXYTRYPTOPHAN; ANTIDEPRESSANT AGENT; CITALOPRAM; CLOMIPRAMINE; FENFLURAMINE; FLUOXETINE; FLUVOXAMINE; IPSAPIRONE; PAROXETINE; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRYPTOPHAN;

CLINICAL RESEARCH; DRUG MECHANISM; HUMAN; PANIC; PRIORITY JOURNAL; REVIEW; SEROTONINERGIC SYSTEM; TREATMENT OUTCOME; TREATMENT PLANNING;

ANTIDEPRESSIVE AGENTS; CLOMIPRAMINE; FLUOXETINE; HUMANS; PANIC DISORDER; RAPHE NUCLEI; RECEPTORS, SEROTONIN; SEROTONIN; SEROTONIN AGENTS; SEROTONIN UPTAKE INHIBITORS;

EID: 0031902232     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (25)

1. Mavissakalian M, Perel IM. Imipramine dose response relationship in panic disorder with agoraphobia. Arch Gen Psychiatry 1988;46:127-131
2. den Boer J, Westenberg H. Effect of a serotonin and noradrenaline uptake inhibitor in panic disorders: a double blind comparative study with fluvoxamine and maprotiline. Int Clin Psychopharmacol 1988;3:59-74
3. Fahy TJ, O'Rourke D, Brophy J, et al. The Galway study of panic disorder, I: clomipramine and lofepramine in DSM-III-R panic disorder: a placebo controlled trial. J Affect Disord 1992;25:63-76
4. Graeff FG. Brain defense systems and anxiety. In: Roth M, Burrows GD, Noyes R, eds. Handbook of Anxiety, vol. 3: The Neurobiology of Anxiety. Cambridge, UK: Cambridge University Press; 1990:307-354
5. Deakin JFW, Graeff FG. 5-HT and mechanisms of defence. J Psychopharmacol (Oxf) 1991;5:305-315
6. Graeff FG, Guimeras TS, De Andrade TG. Role of 5-HT in stress, anxiety and depression. Pharmacol Biochem Behav 1996;54:129-141
7. Jenck F, Martin JR, Moreau JL. Animal models of panic disorder: emphasis on face and predictive validity [abstract]. Eur Neuropsychopharmacol 1996;6(suppl 4):S22.01
8. Charney DS, Heninger G. Serotonin function in panic disorder. Arch Gen Psychiatry 1986;43:1059-1065
9. Westenberg H, den Boer J. Serotonin function in panic disorder effect of L-5-hydroxytryptophan in patients and controls. Psychopharmacology (Berl) 1989;98:283-285
10. Targum S. Differential responses to anxiogenic challenge studies in patients with major depressive disorder and panic disorder. Biol Psychiatry 1990;28:21-34
11. George DT, Nutt DJ, Rawlings RR, et al. Behavioral and endocrine responses to clomipramine in panic disorder patients with and without alcoholism. Biol Psychiatry 1995;37:112-119
12. Chamey DS, Woods SW, Goodman WK, et al. Serotonin function in anxiety, II: effects of the serotonin agonist mCPP in panic disorder patients and healthy subjects. Psychopharmacology (Berl) 1987;92:14-24
13. 1A receptor effector system responsivity in panic disorder. Psychopharmacology (Berl) 1992;106: 111-117
14. Kahn RS, Wetzler S, van Pragg HM, et al. Behavioural indications for receptor hypersensitivity in panic disorder. Psychiatry Res 1988;25:101-104
15. Salomon RM, Miller HL, Delgado PL, et al. The use of tryptophan depletion to evaluate central serotonin function in depression and other neuropsychiatric disorders. Int Clin Psychopharmacol 1993;8(suppl 2):41-46
16. Goddard AW, Sholomskas DE, Walton KE. Effects of tryptophan depletion in panic disorder. Biol Psychiatry 1994;36:775-777
17. Miller H, Anderson IM, Deakin JFW. Acute tryptophan depletion increases panic anxiety in panic disorder patients. Behav Pharmacol 1995;6(suppl 1):148
18. Nutt DJ, Cowen PJ. Diazepam alters brain 5-HT function in man: implications for the acute and chronic effects of benzodiazepines. Psychol Med 1987;17:601-607
19. Blier P, de Montigny C, Chaput Y. A role for the serotonin system in the mechanism of action of antidepressant treatments; preclinical evidence. J Clin Psychiatry 1990;51(4, suppl):14-20
20. Hyttel J. Pharmacological characterization of selective serotonin reuptake inhibitors (SSRIs). Int Clin Psychopharmacol 1994;9(suppl 1):19-26
21. Lecrubier Y, Bakker A, Dunbar G, et al. A comparison of paroxetine, clomipramine and placebo in the treatment of panic disorder. Acta Psychiatr Scand 1997;95:145-152
22. Overo KF. Preliminary studies of the pharmacokinetics of citalopram in man. Eur J Clin Pharmacol 1978;14:69-73
23. Boyer WF, Feighner JP. Pharmacokinetics and drug interactions. In: Feighner JP, Boyer WF, eds. Selective Serotonin Reuptake Inhibitors. Chichester, England: John Wiley & Sons; 1991:81-88
24. Milne RJ, Goa KL. Citalopram: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in depressive illness. Drugs 1991;41:450-477
25. Baumann P, Rochat B. Comparative pharmacokinetics of selective serotonin reuptake inhibitors: a look behind the mirror. Int Clin Psychopharmacol 1995;10(suppl 1):10-15